fashion -WSS

fashion

author：comprehensive 2025-10-01 22:17:24 - browse：927

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： FTC sues over Novant Health acquisition of two N.C. hospitals

focus

WSS

Reconstructing family trees of blood cells may help predict disease

Bernie Sanders is gearing up to subpoena pharma CEOs

Humana’s losses in Medicare Advantage tank its stock

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

FTC sues over Novant Health acquisition of two N.C. hospitals

Medicare drug price negotiation legal challenge met with skepticism

hotspot

fashion

entertainment

Continuity nursing helped my family in our darkest PICU moments

American TikTok star stuck in Dubai for months following rental car altercation

The high cost of giving birth even with insurance

Many immigrants are left out of maternal health programs

How to save PrEP access — and even expand it

Venture capital firm's plans to take over Akron hospital face hurdles

Supreme Court strikes down use of affirmative action

New clues to why women have higher risk of autoimmune disorders

Medical records are filled with copy

Merck CEO won’t testify in Senate, citing no expertise in drug prices

knowledge

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Campaign finance charge dropped from case against Sam Bankman

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Campaign finance charge dropped from case against Sam Bankman

FTC sues over Novant Health acquisition of two N.C. hospitals

entertainment

focus

entertainment

entertainment